AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today reported results for the quarter ended June 30, 2025, and provided a corporate update.
– Three active immunotherapies for precision prevention of neurodegeneration progressing through Phase 2 clinical development
– ACI-7104.056 anti-alpha-synuclein active immunotherapy in Parkinson’s disease produced strong immunogenicity and favorable safety profile in interim results from the ongoing Phase 2 VacSYn reported in April, with further data to come in H2 2025
– Third Alzheimer’s disease cohort (AD3) in the Phase 2 ABATE trial of anti-Abeta ACI-24.060 to reach 12 months of treatment in December 2025, with interim results expected early 2026
– Small molecule NLRP3 program now in IND-enabling studies, highlighting promise in early-stage pipeline
– Cash resources of CHF 127.1 million (USD 157.6 million) as of June 30, 2025, provide funding into Q1 2027 excluding any potential milestone payments